

## NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

## DATA SHEET

Reagent:	$\dot{x}$ HIV-1 LAV infected HeLa CD4+ Cells
Catalog Number:	1301
Lot Number:	150051
Release Category:	A
Provided:	$2.6 \times 10^6$ cells/ml. Viability is 90%.
Cell Type:	Human cervical epithelial carcinoma.
Propagation Medium:	DMEM, 90%; fetal bovine serum, 10%.
Freeze Medium:	Fetal bovine serum, 90%; DMSO, 10%.
Growth Characteristics:	Maintain cells at 10 <sup>5</sup> -10 <sup>6</sup> cells/ml.
Morphology:	Cells are mostly adherent, with some clumping. Variable morphology.
Sterility:	Negative for bacteria, fungi, and mycoplasma.
Description:	The HIV-1 LAV infected HeLa CD4+ Cell line was established by infecting HeLa CD4+ cells (cat# 154) with HIV-1 LAV followed by subcloning.
Special Characteristics:	These cells express high levels of all viral proteins, and >90% of them express cell surface gp120. Syncytia formation does not occur. The cells are suitable targets for assays of cell killing because they are susceptible to killing by allogeneic CTL, are easily labeled with <sup>51</sup> Cr, and exhibit a low spontaneous release of <sup>51</sup> Cr. The cells release infectious viral particles.
	Alternate names: neta/LAV

## ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage:	Liquid nitrogen.
Contributor:	Dr. Joerg Berg and Dr. Matthias Wabl.
References:	Berg J, Doe B, Steimer KS, and Wabl M. HeLa-LAV, an epithelial cell line stably infected with HIV-1. <i>J Virol Methods</i> <b>34</b> :173-180, 1991.
	Berg J, Lotscher E, Steimer KS, Capon DJ, Baenziger J, Jack HM, Wabl M. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. <i>Proc Natl Acad Sci USA</i> <b>88</b> :4723-4727, 1991.
NOTE:	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LAV infected HeLa CD4+ Cells from Dr. Joerg Berg and Dr. Matthias Wabl." Also include the references cited above in any publications.
Last Updated	March 28, 2016

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.